# TEPKINLY (epcoritamab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/epcoritamab

> The FDA approved TEPKINLY (epcoritamab), sponsored by GENMAB A/S (GMAB), on February 4, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | TEPKINLY (epcoritamab) |
| Codes | GEN3013 |
| Sponsor | GENMAB A/S (GMAB) https://sec-api.dev/companies/gmab/catalysts |
| Indications | with relapsed or refractory fl, [relapsed or refractory](https://sec-api.dev/indications/relapsed-or-refractory), [Follicular Lymphoma (FL)](https://sec-api.dev/indications/follicular-lymphoma-fl), [Diffuse Large B-Cell Lymphoma](https://sec-api.dev/indications/diffuse-large-b-cell-lymphoma) |
| Modality | antibody |
| FDA designations | accelerated, breakthrough, priority review |

## Timeline

### May 2023: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-11-12, last confirmed 2025-11-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-277733): "Epcoritamab was approved by the FDA and Japan MHLW in May 2023 and September 2023, respectively, and is marketed in the U.S. and Japan under the tradename EPKINLY." https://www.sec.gov/Archives/edgar/data/1434265/000119312525277733/d768286dex993.htm

### Jun 2024: FDA approval

- Status: completed, approved. Date confidence: month. Indication: with relapsed or refractory FL.
- First seen 2025-02-12, last confirmed 2025-02-12.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-000831): "In June 2024, the U.S. FDA approved a second indication for EPKINLY (epcoritamab-bysp), specifically for the treatment of adults with relapsed or refractory FL after two or more lines of systemic therapy." https://www.sec.gov/Archives/edgar/data/1434265/000155837025000831/gmab-20241231xex99d1.htm

### October 13, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Diffuse Large B-cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04628494 (A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Genmab; Results First Posted 2026-11-03." https://clinicaltrials.gov/study/NCT04628494

### October 13, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Diffuse Large B-Cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07226752 (A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Genmab; Results First Posted 2026-11-10." https://clinicaltrials.gov/study/NCT07226752

### November 18, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: relapsed or refractory.
- First seen 2025-11-18, last confirmed 2025-11-18.
- Press release filed with the SEC (EX-99) (accession 0001434265-25-000095): "COPENHAGEN, Denmark; November 18, 2025 - Genmab A/S (Nasdaq: GMAB) announced today that EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) was approved by the U.S. Food and Drug Administration (FDA) for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL)." https://www.sec.gov/Archives/edgar/data/1434265/000143426525000095/gmab_20251118xex99d1.htm

### November 30, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2025-08-07, last confirmed 2025-11-06.
- Press release filed with the SEC (EX-99) (accession 0001434265-25-000061): "•U.S. FDA has accepted for priority review new supplemental Biologics License Application (sBLA) for epcoritamab plus R2, with action date of November 30, 2025" https://www.sec.gov/Archives/edgar/data/1434265/000143426525000061/gmab_20250807xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001434265-25-000092): "Under the PDUFA, the FDA has set a target action date of November 30, 2025." https://www.sec.gov/Archives/edgar/data/1434265/000143426525000092/genmabinterimreportq32025.htm
- Press release filed with the SEC (EX-99) (accession 0001434265-25-000061): "Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of November 30, 2025." https://www.sec.gov/Archives/edgar/data/1434265/000143426525000061/gmab_20250807xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001434265-25-000095): "COPENHAGEN, Denmark; November 18, 2025 - Genmab A/S (Nasdaq: GMAB) announced today that EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) was approved by the U.S. Food and Drug Administration (FDA) for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL)." https://www.sec.gov/Archives/edgar/data/1434265/000143426525000095/gmab_20251118xex99d1.htm

### February 4, 2026: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-02-04, last confirmed 2026-02-04.
- Press release filed with the SEC (EX-99) (accession 0001551152-26-000004): "•AbbVie announced the FDA approval of Epkinly (epcoritamab) in combination with rituximab and lenalidomide (R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL)." https://www.sec.gov/Archives/edgar/data/1551152/000155115226000004/abbv-20251231xexhibit991.htm

### June 10, 2026: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 2. Indication: Diffuse Large B-Cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05660967 (Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-06-10 (ACTUAL); Lead Sponsor Genmab." https://clinicaltrials.gov/study/NCT05660967

### October 5, 2026: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3.
- First seen 2026-10-05, last confirmed 2026-10-05.
- Press release filed with the SEC (EX-99) (accession 0001434265-26-000132): "Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of 2 to 5." https://www.sec.gov/Archives/edgar/data/1434265/000143426526000132/gmab_20261015xex99d1.htm

### November 3, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Diffuse Large B-cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04628494 (A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Genmab; Results First Posted 2026-11-03." https://clinicaltrials.gov/study/NCT04628494?tab=results

### November 10, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Diffuse Large B-Cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07226752 (A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Genmab; Results First Posted 2026-11-10." https://clinicaltrials.gov/study/NCT07226752?tab=results

### March 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Diffuse Large B-Cell Lymphoma; Classic Follicular Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05451810 (A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Genmab." https://clinicaltrials.gov/study/NCT05451810

### Mar to Jun 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Diffuse Large B-Cell Lymphoma; Classic Follicular Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05451810 (A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Genmab." https://clinicaltrials.gov/study/NCT05451810

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Diffuse Large B-Cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05578976 (A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Genmab." https://clinicaltrials.gov/study/NCT05578976

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Diffuse Large B-Cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05578976 (A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Genmab." https://clinicaltrials.gov/study/NCT05578976

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Diffuse Large B-Cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06508658 (A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Genmab." https://clinicaltrials.gov/study/NCT06508658

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Diffuse Large B-Cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06508658 (A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Genmab." https://clinicaltrials.gov/study/NCT06508658

### December 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Follicular Lymphoma (FL).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05409066 (Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Genmab." https://clinicaltrials.gov/study/NCT05409066

### Dec 2029 to Mar 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Follicular Lymphoma (FL).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05409066 (Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Genmab." https://clinicaltrials.gov/study/NCT05409066

## Same indication

- [Calquence (acalabrutinib)](https://sec-api.dev/pdufa/acalabrutinib) (AZN)
- [GTB-3650](https://sec-api.dev/pdufa/gtb-3650) (GTBP)
- [Ordspono™ (odronextamab)](https://sec-api.dev/pdufa/odronextamab) (REGN)
- [Revuforj® (revumenib)](https://sec-api.dev/pdufa/revumenib) (SNDX)
- [Tisagenlecleucel](https://sec-api.dev/pdufa/tisagenlecleucel) (NVS)
- [KOMZIFTI (ziftomenib)](https://sec-api.dev/pdufa/ziftomenib) (KURA)
- [Zilovertamab vedotin](https://sec-api.dev/pdufa/zilovertamab-vedotin) (MRK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/epcoritamab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TEPKINLY (epcoritamab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/epcoritamab

```bibtex
@misc{secapidev_pdufa_epcoritamab_20261116,
  title        = {TEPKINLY (epcoritamab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/epcoritamab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_epcoritamab_20261116","title":"TEPKINLY (epcoritamab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/epcoritamab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
